Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity (Q39400167)

11 September 2017

title

Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity (English)

1 reference

11 September 2017

0 references

1 reference

1 reference

Miyako Takata

1

1 reference

11 September 2017

Hiroki Chikumi

2

1 reference

11 September 2017

Naomi Miyake

3

1 reference

11 September 2017

Kaori Adachi

4

1 reference

11 September 2017

Yasunobu Kanamori

5

1 reference

11 September 2017

Akira Yamasaki

6

1 reference

11 September 2017

Tadashi Igishi

7

1 reference

11 September 2017

Naoto Burioka

8

1 reference

11 September 2017

Eiji Nanba

9

1 reference

11 September 2017

Eiji Shimizu

10

1 reference

11 September 2017

publication date

1 April 2012

1 reference

Cancer Biology and Therapy

11 September 2017

published in

1 reference

11 September 2017

volume

13

1 reference

11 September 2017

issue

6

1 reference

11 September 2017

page(s)

369-378

1 reference

describes a project that uses

11 September 2017

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

Autocrine, paracrine and juxtacrine signaling by EGFR ligands

21 January 2018

1 reference

EGFR and cancer prognosis

21 January 2018

1 reference

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody

21 January 2018

1 reference

Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines

21 January 2018

1 reference

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway

21 January 2018

1 reference

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer

21 January 2018

1 reference

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

21 January 2018

1 reference

Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.

21 January 2018

1 reference

Regulation of Akt signaling activation by ubiquitination

21 January 2018

1 reference

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy

21 January 2018

1 reference

Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification

21 January 2018

1 reference

Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers

21 January 2018

1 reference

Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.

21 January 2018

1 reference

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

21 January 2018

1 reference

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

21 January 2018

1 reference

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

21 January 2018

1 reference

Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study

21 January 2018

1 reference

Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2.

21 January 2018

1 reference

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.4161/CBT.19238

1 reference

11 September 2017

1 reference